Sign in

CIK 0000899923

  • Accelerated filer

MYRIAD GENETICS INC

Sign in to watch
Ticker
MYGN
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
870494517
Phone
+1 801-584-3600
Business address
322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
Former names
MYRIAD GENETICS INC
  1. 4 Grant or award President and CEO acquired 197,023 shares (grant or award)
  2. 4 Grant or award Chief Scientific Officer acquired 28,459 shares (grant or award)
  3. 4 Grant or award Chief Technology Officer acquired 28,459 shares (grant or award)
  4. 4 Grant or award Chief Accounting Officer acquired 6,000 shares (grant or award)
  5. 4 Grant or award Chief Commercial Officer acquired 39,405 shares (grant or award)
  6. 4 Open-market sale Chief Financial Officer sold 15,000 shares at $22.55 ($338,253)
  7. 4 Open-market sale Chief Operating Officer sold 13,184 shares at $22.74 ($299,823)
  8. 4 Grant or award Chief People Officer acquired 15,856 shares (grant or award)
  9. 3 Insider Initial Statement of Ownership
  10. 4 Insider Changes in Ownership
  11. 4 Shares withheld for taxes SVP, Chief of Staff gave up 2,556 shares (to pay taxes)
  12. 4 Shares withheld for taxes Chief Technology Officer gave up 1,012 shares (to pay taxes)
  13. 4 Shares withheld for taxes Chief Financial Officer gave up 11,222 shares (to pay taxes)
  14. 4 Open-market sale Chief Financial Officer sold 9,400 shares at $20.04 ($188,386)
  15. 4 Open-market sale Chief Financial Officer sold 600 shares at $20.01 ($12,006)
  16. 4 Shares withheld for taxes Chief Scientific Officer gave up 302 shares (to pay taxes)
  17. 4 Shares withheld for taxes Chief Operating Officer gave up 853 shares (to pay taxes)
  18. 4 Open-market sale Chief Financial Officer sold 20,000 shares at $15.15 ($302,992)
  19. 4 Grant or award Director acquired 16,875 shares (grant or award)
  20. 3 Insider Initial Statement of Ownership

Page 12 of 65 · 1,293 filings